Chaur-Dong Hsu, MD, MPH, FACOG
Emmanuelle J Meuillet, PhD
Associate Research Professor of Nutritional Sciences




Molecular and Cellular Pharmacology and Pharmacochemistry, INSERM U338, University Louis Pasteur, Strasbourg, France



Molecular and Cellular Pharmacology and Pharmacochemistry, INSERM U338 University Louis Pasteur, Strasbourg, France (Diplôme d'Études Approfondies)



Biochemistry and Physiology, University Louis Pasteur, Strasbourg, France


Emmanuelle J. Meuillet received her PhD in Biochemistry and Pharmacology from the Louis Pasteur University in Strasbourg (France) in 1995. She then completed a post-doctoral fellowship at the Childrens' Memorial Hospital at Northwestern University (Chicago, IL) from 1996 to 1999. She arrived at the University of Arizona (Tucson, AZ) in 1999 where she holds the rank of Associate Professor with Tenure at the Arizona Cancer Center since 2000. Her cancer research program has been continuously funded by the National Institute for Health (NIH), by the State of Arizona and by several foundations including the Hirshberg Foundation for Research on Pancreatic Cancer. Her research resulted in co-founding a biotech start-up named Phusis Therapeutics, Inc. (San Diego, CA) in 2009. She is a consultant for the NIH, foundations and various organizations in the US and Europe. She is the author of more than fifty manuscripts and reviews on cancer and holds 2 patents.

Back in France since February 2014, Emmanuelle Meuillet has set up a research program, funded by the Toulouse Cancer Sante Foundation, at the ITAV (Institute of Advanced Technologies for the Living) at the Pierre Potier Center in Toulouse on the Oncopole campus. The topic remains in oncology and more particularly on the metastases of aggressive cancers. In April 2016, she created Theraxen Technologies, which valorizes her work with the support of the Toulouse Tech Transfer office.


Research Interest

Brain Tumor, Breast Cancer, Cancer Prevention, Colon-Colorectal Cancer, Inflammatory Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Nutrition, Pancreatic Cancer, Prostate Cancer, Skin Cancer, Squamous Cell Carcinoma.

Scientific Activities:

Teaching Experience:


Co-Founder and Member, Theraxen Technologies USA, LLC (Tucson, USA)


Co-Founder and CEO, Theraxen Technologies, SAS (Toulouse, FR)


Research Associate Professor, Department of Nutritional Sciences, The University of Arizona, Tucson, USA


Scientist, ITAV-CNRS USR3505, Toulouse (FR)


Visiting Professor, University Paul Sabatier III, Toulouse (FR)


Associate Professor, Department of Nutritional Sciences, The University of Arizona, Tucson, USA


Associate Professor, Joint Appointment, BIO5 Institute for Collaborative BioResearch, The University of Arizona, Tucson, USA


Co-Founder, PHusis Therapeutics Inc., Houston, USA


Assistant Professor, Joint Appointment, Department of Molecular and Cellular Biology, The University of Arizona, Tucson, USA


Assistant Professor, Department of Nutritional Sciences, The University of Arizona, Tucson, USA


Assistant Professor, Joint Appointment, BIO5 Institute for Collaborative BioResearch, The University of Arizona, Tucson, USA


Research Assistant Professor, Molecular and Cellular Biology Department, The University of Arizona, Arizona Cancer Center, Tucson, USA


Research Associate, Arizona Cancer Center, The University of Arizona, Tucson, USA
Research Project: Inhibitors of Akt as anticancer drugs.
Mentor: Garth Powis, PhD


Postdoctoral Researcher, Children’s Memorial Hospital, Chicago, USA
Research Project: Modulation of receptor tyrosine kinase signaling by membrane
Mentor: Eric G. Bremer, PhD


Postdoctoral Researcher, Chicago Institute of Neurosurgery and Neuroresearch, Chicago, USA
Research Project: Sialidase gene transfection alters epidermal growth factor receptor signaling in human epidermoid carcinoma cell line, A431.
Mentors: Eric G. Bremer, PhD and Joseph R Moskal, PhD


Graduate Research Assistant, Neurochemistry Center - INSERM U338, Strasbourg, FR Advisor: Gerard Crémel, PhD


Research Assistant, Laboratory of Molecular Biology and Crystallography, Institut de Biologie Moléculaire et Cellulaire (IBMC), Centre National de la Recherche Scientifique (CNRS), Strasbourg, FR.
Advisors: Dino Moras, PhD and Alberto Podjarny, PhD


Research Assistant, Control Quality Laboratory (LAREBRON), Illkirch-Graffenstaden, FR. Advisor: J. Delmas, PhD

Professional Activities:

2016– present 

Review Board Member, Pancreas-Open Journal (Open Access)

2016– present 

National Institute of Health (NIH) Study Section Ad-Hoc Reviewer ZCA1 RTRB-4 (J1) S: NCI Clinical and Translational R21 (SEP-3) (November 2016)

2016– present 

NIH Study Section Ad-Hoc Reviewer ZCA1 SRB-8 (O1): NCI Omnibus R03 (Jun. 2016)

2015– present 

NIH Study Section Ad-Hoc Reviewer Program Project Grant IMST - J (40) (Jun. 2015; Jun. 2016)

2013– present

Editorial Advisory Board Member for Metabolomics

2012 – present

Editorial Board Member for Journal of Cytology and Molecular Biology

2012 – present

Editorial Advisory Board Member for Cancer Metabolomics

2012 – present

NIH Study Section Ad-Hoc Reviewer for the Drug Discovery and Molecular Pharmacology Study Section (DMP) (Oct. 2012, Feb. 2013, Feb. 2014, Oct. 2014, Jun 2015, Feb 2016, Feb 2017).

2012 – 2014   

Department of Defense (DOD), Tuberous Sclerosis Complex Research Program, Experimental Therapies and Diagnosis Panel, Scientist Reviewer

2011 – 2014   

Journal of Investigative Dermatology, Ad hoc Reviewer

2011 – 2014   

American Heart Association, Scientist Reviewer

2009 – 2010   

American Association for Cancer Research, Organizing Committee

2008 – 2014   

Molecular Cancer Therapeutics, Ad hoc Reviewer

2008 – 2014   

Cancer Research, Ad hoc Reviewer

2008 – 2014   

Carcinogenesis, Ad hoc Reviewer

2008 – 2014   

Journal of Nutrition, Ad hoc Reviewer

2006 – 2014   

More Graduate Education @ Mountain States Alliance (MGE@MSA), Member

2005 – 2014   

DOD, Breast Cancer Research Program, Cell Biology 3 Panel, Scientist Reviewer

2005 – 2014   

DOD, Prostate Cancer Research Program, Scientist Reviewer

2004 – 2006   

American Diabetes Association, Member

2004 – 2010   

American Society of Nutritional Sciences, Member

2004 – 2008   

European Association for Cancer Research, Member

1999 – 2015   

American Association for Cancer Research, Member

1996 – 1998   

Association Française Retinitis Pigmentosa (AFRP), Member

1995 – 1996   

Neuroscience Society, Member

Honors & Awards


Nomination – “Innovator of the Year” – La Tribune (Toulouse, France)


Best Publication Award - Metabolomics Society & Springer – San Francisco, CA, USA


S. Salmon Junior Investigator Award


Mortar Board Senior Honor Society Award


Fellowship, Wakonse Conference on College Teaching, Wakonse Foundation


Honorable Mention, The Nancy R. Gelman Foundation, New York, NY


VA REAP Award, Co-principal investigator: Tumor Angiogenesis in Basal Cell Carcinoma ($850,000)


Postdoctoral Fellowship, National Institutes of Health, National Cancer Institute


Postdoctoral Award, The Gus Foundation, Chicago, IL


Travel Award, National Science Foundation (for Glyco XIV, Zurich)


Postdoctoral Award, Association Française Retinitis Pigmentosa (AFRP), Colomiers, France


Postdoctoral Travel Award, Medical Research Foundation (France)


PhD Fellowship, French Government (Ministère de Recherche et Technologie, MRT)


DEA Fellowship, French Government



  1. Crémel G, Ficková M, Klimeš I, Leray C, Leray V, Meuillet E, Roques M, Staedel C, Hubert P. (1993) Lipid modulation of insulin receptor tyrosine kinase in cultured cells, animals, and reconstituted systems. In Klimeš I, Howard BV, Storlien LH, Šeböková E, Eds. "Dietary Lipids and Insulin Action: Proceedings of the Second International Smolenice Insulin Symposium". Ann NY Acad Sci 683:164-171.
  2. Meuillet EJ, Crémel G, Forster V, Guerold B, Hicks D, Dreyfus H. (1995) GM3 effects on growth factor receptors in the retina. Publication in IPSEN Books. Ophthalmology Meetings, 7:155-163.
  3. Meuillet E, Crémel G, Hicks D, Dreyfus H. (1996) Ganglioside effects on basic fibroblast and epidermal growth factor receptors in retinal glial cells. J Lipid Mediat Cell Signal 14(1‑3):277-288.
  4. Meuillet E, Crémel G, Dreyfus H, Hicks D. (1996) Differential modulation of basic fibroblast and epidermal growth factor receptor activation by ganglioside GM3 in cultured retinal Muller glia. GLIA 17(3):206-216.
  5. Rebbaa A, Yamamoto H, Saito T, Meuillet E, Kim P, Kersey DS, Bremer EG, Taniguchi N, Moskal JR. (1997) Gene transfection-mediated overexpression of beta1,4-N-acetylglucosamine bisecting oligosaccharides in glioma cell line U373 MG inhibits epidermal growth factor receptor function. J Biol Chem 272(14):9275-9279.
  6. Meuillet E, Wiernsperger N, Hubert P, Crémel G. (1997) Biguanide effects on insulin signaling. In Klimes I, Haffner SM, Šeböková E, Howard BV, Storlein LH, Eds. “Lipids and Syndromes of Insulin Resistance: From Molecular Biology to Clinical Medicine”. Ann NY Acad Sci 827:546-549.
  7. Dreyfus H, Meuillet E, Guerold B, Fontaine V, Forster V, Heidinger V, Sahel J, Hicks D. (1997) Ganglioside and neurotrophic growth factor interactions in retinal neuronal and glial cells. Ind J Biochem Biophys 34(1-2):90-96.
  8. Meuillet EJ, Bremer EG. (1998) Growth factor receptors as targets for therapy in pediatric brain tumors. Pediatr Neurosurg 29(1):1-13.
  9. Dreyfus H, Sahel J, Heidinger V, Mohand-Said S, Guerold B, Meuillet E, Fontaine V, Hicks D. (1998) Gangliosides and neurotrophic growth factors in the retina. Molecular interactions and applications as neuroprotective agents. In Ledeen RW, Hakomori SI, Yates AJ, Schneider JS, Yu RK, Eds. “Sphingolipids as Signaling Modulators in the Nervous System”. Ann NY Acad Sci 845:240-252.
  10. Meuillet EJ, Wiernsperger N, Mania-Farnell B, Hubert P, Crémel G. (1999) Metformin modulates insulin receptor signaling in normal and cholesterol-treated human hepatoma cells (HepG2). Eur J Pharmacol 377(2-3):241-252.
  11. Meuillet EJ, Leray V, Hubert P, Leray C, Crémel G. (1999) Incorporation of exogenous lipids modulates insulin signaling in the hepatoma cell line, HepG2. Biochim Biophys Acta 1454(1):38-48.
  12. Meuillet EJ, Kroes R, Yamamoto H, Warner TG, Ferrari J, Mania-Farnell B, George D, Rebbaa A, Moskal JR, Bremer EG. (1999) Sialidase gene transfection enhances epidermal growth factor receptor activity in an epidermoid carcinoma cell line, A431. Cancer Res 59(1):234-240.
  13. Meuillet EJ, Mania-Farnell B, George D, Inokuchi JI, Bremer EG. (2000) Modulation of EGF receptor activity by changes in the GM3 content in a human epidermoid carcinoma cell line, A431. Exp Cell Res 256(1):74-82.
  14. Hu YH, Meuillet EJ, Qiao LX, Berggren MM, Powis G, Kozikowski AP. (2000) Synthesis and Akt inhibitory properties of a 1D-3,4-dideoxyphosphatidyl-inositol ether lipid. Tetrahedron Lett 41(39):7415-7418.
  15. Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A, Powis G, Kozikowski AP. (2000) 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem 43(16):3045-3051.
  16. Rong SB, Hu Y, Enyedy I, Powis G, Meuillet EJ, Wu X, Wang R, Wang S, Kozikowski AP. (2001) Molecular modeling studies of the Akt PH domain and its interaction with phosphoinositides. J Med Chem 44(6):898-908.
  17. Wang X, Rahman Z, Sun P, Meuillet E, George D, Bremer EG, Al-Qamari A, Paller AS. (2001) Ganglioside modulates ligand binding to the epidermal growth factor receptor. J Invest Derm 116(1):69-76.
  18. Hu Y, Meuillet EJ, Berggren M, Powis G, Kozikowski AP. (2001) 3-Deoxy-3 substituted-D-myo-inositol imidazolyl ether lipid phosphates and carbonate as inhibitors of the phosphatidylinositol 3-kinase pathway and cancer cell growth. Bioorg Med Chem Lett 11(2):173-176.
  19. Sun HY, Reddy GB, George C, Meuillet EJ, Berggren M, Powis G, Kozikowski AP. (2002) Synthesis and biological activity of 3-hydroxy(phosphono)methyl-bearing phosphatidylinositol ether lipid analogues. Tetrahedron Lett 43(15):2835-2838.
  20. Miljan EA, Meuillet EJ, Mania-Farnell B, George D, Yamamoto H, Simon HG, Bremer EG. (2002) Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J Biol Chem 277(12):10108-10113.
  21. Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, Ambrad AA, Meuillet EJ, Martinez JD. (2003) Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 (‘Iressa’). Cancer Lett 202(1):43-51.
  22. Meuillet EJ, Mahadevan D, Vankayalapati H, Berggren M, Williams R, Coon A, Kozikowski AP, Powis G. (2003) Specific inhibition of Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol analogues. Mol Cancer Ther 2(4):389-399.
  23. Meuillet EJ, Ihle N, Baker AF, Gard JM, Stamper C, Williams R, Coon A, Mahadevan D, George BL, Kirkpatrick L, Powis G. (2004) In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol Res 14(10):513-527.
  24. Meuillet E, Stratton S, Cherukuri DP, Goulet AC, Kagey J, Porterfield B, Nelson MA. (2004) Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. J Cell Biochem 91(3):443-458.
  25. Meuillet EJ, Mahadevan D, Berggren M, Coon A, Powis G. (2004) Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN’s lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN’s tumor suppressor activity. Arch Biochem Biophys 429(2):123-133.
  26. List AF, Glinsmann-Gibson B, Stadheim C, Meuillet EJ, Bellamy W, Powis G. (2004) Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol 32(6):526-535.
  27. Jean-Louis S, Akare S, Ali MA, Mash EA Jr., Meuillet E, Martinez JD. (2006) Deoxycholic acid induces intracellular signaling through membrane perturbations. J Biol Chem 281(21):14948-14960.
  28. Song Z, Saghafi N, Gokhale V, Brabant M, Meuillet EJ. (2007) Regulation of the activity of the tumor suppressor PTEN by thioredoxin in Drosophila melanogaster. Exp Cell Res 313(6):1161-1171.
  29. Cherukuri DP, Chen XB, Goulet AC, Young RN, Han Y, Heimark RL, Regan JW, Meuillet E, Nelson MA. (2007) The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res 313(14):2969-2979.
  30. Mahadevan D, Powis G, Mash EA, George B, Gokhale VM, Zhang S, Shakalya K, Du-Cuny L, Berggren M, Ali MA, Jana U, Ihle N, Moses S, Franklin C, Narayan S, Shirahatti N, Meuillet EJ. (2008) Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol Cancer Ther 7(9):2621-2632.
  31. James BP, Staatz WD, Wilkinson ST, Meuillet E, Powis G. (2009) Superoxide dismutase is regulated by LAMMER kinase in Drosophila and human cells. Free Radic Biol Med 46(6):821-827.
  32. Berggren M, Sittadjody S, Song Z, Samira JL, Burd R, Meuillet EJ. (2009) Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells. Nutr Cancer 61(3):322-331.
  33. Dexheimer TS, Carey SS, Zuohe S, Gokhale VM, Hu XH, Murata LB, Maes EM, Weichsel A, Sun D, Meuillet EJ, Montfort WR, Hurley LH. (2009) NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III1. Mol Cancer Ther 8(5):1363-1377.
  34. Moses SA, Ali MA, Zuohe S, Du-Cuny L, Zhou LL, Lemos R, Ihle N, Skillman AG, Zhang S, Mash EA, Powis G, Meuillet EJ. (2009) In vitro and in vivo activity of novel small molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res 69(12):5073-5081.
  35. Block KM, Wang H, Szabó LZ, Polaske NW, Henchey LK, Dubey R, Kushal S, László CF, Makhoul J, Song Z, Meuillet EJ, and Olenyuk BZ. (2009) Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine. J Amer Chem Soc 131(50):18078-18088.
  36. Du-Cuny L, Zuohe S, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S. (2009) Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain. Bioorg Med Chem 17(19):6983-6992.
  37. Meuillet EJ, Ihle N, Lemos R, Moses SA, Song Z, Zhang S, Mash EA, Powis G (2010). Molecular pharmacology and antitumor activity of PH-427 a novel AKT/PDK1 pleckstrin homology domain inhibitor. Mol Cancer Ther 9(3):706-717.
  38. Rosenberg D, Meuillet EJ, Nakanishi M. (2010) Prostaglandin E2 synthase and cancer (2010). A comprehensive invited review, Special Issue in Biochimie “Phospholipase A2 and Lipid Mediators”. 92(6):660-664.
  39. Du-Cuny L, Morrow JK, Chen L, Meuillet EJ, Powis G, Mash EA, Zhang S (2011). Recent development of anticancer therapeutics targeting the Akt pathway. Recent Patents on Anti-cancer Drug Discovery. 6(1):146-59.
  40. Ali MA, Zhou LL, Moses S, Zuohe S, Ghosh SC, Du-Cuny L, Lemos R, Ihle N, Zhang S, Powis G, Meuillet EJ, Mash EA. (2011) Development of sulfonamide Akt PH domain inhibitors. Bioorg. Med. Chem 19(6):2046-54.
  41. Meuillet, EJ. (2011) Novel Inhibitors of AKT: Assessment of a Different Approach Targeting the Pleckstrin Homology Domain. Current Medicinal Chemistry 18(18):2727-42.
  42. Chang HH, Song Z, Wisner L, Tripp T, Gokhale V, Meuillet EJ. (2012) Identification of a novel class of mPGES-1 inhibitor with anti-tumor activity in colorectal and lung cancer models. Invest. New Drugs. 305(5): 1865-77.
  43. Chang HH, and Meuillet EJ. (2011) Identification and development of mPGES-1 inhibitors: Where we are at? Fut. Med. Chem. 3(15):1909-34.
  44. Smith B, Chang HH, Medda F, Gokhale V, Dietrich J, Davis A, Meuillet EJ, Hulme C. (2012) Synthesis and Biological Activity of 2-Aminothiazoles as Novel Inhibitors of PGE2 Production in Cells. Bioorg. Med. Chem. Let. 22(10):3567-70.
  45. Jandova J, Beyer TE, Meuillet EJ and Watts GS (2012). The matrix protein CCN1/CYR61 is required for αVβ5-mediated cancer cell migration. Cell Biochem. Funct. 30(8):687-95.
  46. Stephen RM, Baker A, Brown K, Meuillet EJ, Gillies B. (2012). Tumorigenicity, pAkt and diffusion MRI in early passage breast cancer cell lines. Exp. Biol. Med. 237(11):1273-80.
  47. Medda F, Sells E, Chang HH, Dietrich J, Chappeta S, Smith B, Gokhale V, Meuillet EJ and Hulme C. (2013) Synthesis and biological activity of aminophthalazines and aminopyridazines as novel inhibitors of PGE2 production in cells. Bioorg. Med. Chem. Let. 23(2):528-231.
  48. Sells E, Norberg J and Meuillet EJ. (2013) Targeting mPGES-1 for inflammatory-related diseases: a novel way to regulate PGE2? Pharmaceutical Patent Analyst, 2(2):265-288.
  49. Cantoria M, Lugunero T, Boros LG and Meuillet EJ. (2014) Contextual Synthetic Inhibition of Fatty Acid Synthesis by Metformin Involves Glucose-derived Acetyl-CoA, K-ras and Cholesterol in Pancreatic Tumor Cells. Metabolomics 10(1):91-104.
  50. Cantoria MJ, Patel H, Boros LG and Meuillet EJ (2014) Metformin and Pancreatic Cancer Metabolism. In Pancreatic Cancer – Insights into molecular mechanisms and novel approaches to early detection and treatment” Edited by Kelly McCall, ISBN 978-953-51-1375-1, InTech, DOI: 10.5772/57432, Chapter 7.
  51. Boros LG, Beger RD, Somlyai G, Colca JR, Szalma S, Thompson PA and Meuillet EJ (2014) Targeted tracer fate associations in drug efficacy testing in cancer. In Tumor Cell Metabolism – Pathways, Regulation and Biology, Sybille Mazurek and Maria Shoshan (Eds.); Springer-Verlag Gmbh, Heidelberg, Germany, European Union. pp349-371.
  52. Lucero-Acuna A, Moses SA, Jeffrey J, Abril ER, Nagle R, Guzman R, Pagel MD, and Meuillet EJ (2014) Nanoparticles delivery of a novel AKT/PDK1 inhibitor inhibits pancreatic cancer tumor growth and metastasis. Int. J. Nanomed. 4(9): 5653-65. PMC 4263440.
  53. Chen L, Du-Cuny L, Moses S, Dumas S, Song Z, Meuillet EJ, Zhang S.(2015) In silico discovery and experimental evaluation of small-molecule inhibitors targeting GAB1 pleckstrin homology domain. PLoS Computational Biology 11(1):e1004021 PMCID: PMC4287437
  54. Joerg M. Buescher, Maciek R. Antoniewicz, Laszlo G. Boros, Shawn C. Burgess, Henri Brunengraber, Clary B. Clish, Ralph J. DeBerardinis, Olivier Feron, Christian Frezza, Bart Ghesquiere, [......], Emmanuelle Meuillet, Gregory Stephanopoulos, Julie St-Pierre, Daniel A. Tennant, Christoph Wittmann, Matthew G. Vander Heiden, Alexei Vazquez, Karen Vousden, Jamey D. Young, Nicola Zamboni, Sarah-Maria Fendt (2015) A roadmap for interpreting 13C metabolite labeling patterns from cells. Current Opinion in Biotechnol. 34: 189-201.
  55. Nakanishi M, Horelik N, Meuillet EJ, and Rosenberg DW. (2015) Non-cell autonomous effects of targeting inducible PGE2 synthesis during inflammation-associated colon tumorigenesis. Carcinogenesis 36(4):478-486. PMC 4392604.
  56. Boros LG, D’Agostino DP, Katz HE, Roth JP, Meuillet, EJ and Somlyai G. (2016) Submolecular regulation of cell transformation by deuterium depleting water exchange reation in the tricarboxylic acid substrate cycle. Medical Hypothesis 87:69-74. PMC 4733494.
  57. Kobes EJ, Daryaei I, Howison C, Bontrager JG, Sirianni RW, Meuillet EJ and Pagel MD. (2016) Improved treatment of pancreatic cancer with drug delivery nanoparticles loaded with a novel AKT/PDK1 inhibitor. Pancreas.45(8): 1158-66. PMCID 4983222.



Journal of Breast Cancer Research and Advancements